Amnis Introduces New FlowSight Imaging Flow Cytometer

14 Jun 2011
Share
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the launch of the new FlowSight imaging flow cytometer.

The FlowSight is a compact and affordable 12-channel flow cytometer with unrivalled fluorescence sensitivity and the breakthrough ability to produce imagery of every cell. The modular FlowSight can be upgraded in the factory or the field with up to four lasers, a 96-well AutoSampler, and a Quantitative Imaging package, thereby providing the capabilities and flexibility to meet the needs of a broad range of users.

“With 12 detection channels, visual verification of every cell, and affordable pricing, the FlowSight is designed to serve the needs of beginners and expert flow cytometrists alike,” said David Basiji, Ph.D., Amnis’ Chief Executive Officer. Basiji added, “The FlowSight complements Amnis' flagship ImageStreamX imaging flow cytometer, a high resolution microscope for cells in fluid suspension that enables numerous image-based assays in rare sub-populations.”

“The FlowSight is based on the proven ImageStreamX architecture and shares its remarkable fluorescence sensitivity, exceeding that of high-end conventional flow cytometers by five-fold or more,” remarked William Ortyn, Amnis’ President and COO. “With the FlowSight, Amnis is fulfilling its promise to bring cell imaging to the larger flow cytometry market,” added Ortyn.

Request Info


Company website

EMD Millipore, a division of Merck KGaA, Darmstadt, Germany